Navigation Links
Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
Date:10/29/2009

ies to people afflicted with these diseases. We remain fully committed to the success of Amicus," concluded John F. Crowley.

Financial Guidance:

Based on current projections of net operating expense, the Company reiterates its expectation to end 2009 with approximately $70-$80 million in cash, cash equivalents and marketable securities. Additionally, the Company expects that its current cash, cash equivalents and marketable securities together with the fourth quarter $5.2 million payment from Shire will be sufficient to fund operations and capital expenditure requirements into the second half of 2011.

Third Quarter 2009 Results Summary

On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0.59 per share ($0.51 per share on a non-GAAP basis) for the three months ended September 30, 2009. As of September 30, 2009, cash, cash equivalents and marketable securities totaled $89.3 million.

Clinical Program Updates

Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease

In the second quarter of 2009, Amicus announced that the Company reached agreement with the FDA on the key protocol design elements of its pivotal trial, including the use of the surrogate primary endpoint of the change in the amount of kidney interstitial capillary GL-3, the substrate that accumulates in the cells of Fabry patients. In addition, the FDA is in agreement that the Company is eligible to seek Accelerated Approval for Amigal according to Subpart H regulations. Amicus began submitting the Phase 3 protocol to investigational sites worldwide in June 2009 and patient enrollment and dosing are now underway.

Furthermore, Amicus previously reported that it completed a series of discussions with the EMEA regarding the clinical study requ
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Calif. , April 17, 2015 /PRNewswire/ ... received a SBIR grant from the National ... National Institutes of Health (NIH). The grant ... efforts in the development of breakthrough genomic ... using specially fabricated substrates. Centrillion has been ...
(Date:4/17/2015)... - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF), a ... commercializes proprietary technologies and products for advanced microarray ... approval from the TSX Venture Exchange to extend ... warrants ("the Warrants") of the Company, which were ... private placement financing. Each Warrant entitles ...
(Date:4/17/2015)... April 17, 2015 Global Stem ... GTCbio Stem Cell Summit 2015 April 27 - 29, ... latest developments in all areas of stem cell research ... stem cells and regenerative medicine. , The conference ... as well as translational research in stem cell therapies, ...
(Date:4/16/2015)... 2015 Spirax Sarco, the leader ... their newly designed, state-of-the-art website in the first ... effectively promotes the Spirax Sarco brand, company capabilities, ... that a site visitor might be looking for ... industries serviced, the latest company news, careers, and ...
Breaking Biology Technology:SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3Spirax Sarco website has a new look 2
... , INDIANAPOLIS , ... and manufacturing companies continued to expand in 2009, despite challenges ... in the economy, the prospect of healthcare reform and other ... announced, and service line extensions were added by companies such ...
... , New kinase array designed for ... VANCOUVER , Feb. 10 /PRNewswire/ - ... novel Protein Kinase Microarray with 200 recombinant human protein ... applications for drug target counter screening, to identify novel ...
... ... users to search the most sought after jobs in the industry anytime, anywhere. ... (PRWEB) -- MedReps.com gives members ... on the web. But in a competitive market like medical sales, job seekers need every ...
Cached Biology Technology:Indiana Biopharmaceutical Service Providers Maintain Steady Growth Despite Industry Challenges 2Indiana Biopharmaceutical Service Providers Maintain Steady Growth Despite Industry Challenges 3Indiana Biopharmaceutical Service Providers Maintain Steady Growth Despite Industry Challenges 4Kinexus Announces the Launch of a New Protein Kinase Microarray 2With the MedReps.com iPhone App, the Medical Sales Job Search Goes Mobile 2
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ( ... Voice Biometrics - Global Strategic Business Report" report to their ... and Voice Biometrics in US$ Thousands by the following Segments: Face ... the US, Canada , Japan ... Middle East & Africa ...
(Date:3/23/2015)... --  HOYOS Labs , a leading global authentication infrastructure ... Company will demonstrate multiple biometrics-based technologies under its identity ... on March 23 through 25, 2015, in ... IEEE Biometric Open Protocol Standard; free biometrics-based consumer app, ... system. BOPS was invented by HOYOS Labs and contributed ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... can be a shrewd hunter himself. A University of ... lures to hunt their prey. Vladimir Dinets, ... is the first to observe two crocodilian speciesmuggers and ... during nest-building time. The research is published ...
... of the University of Massachusetts Medical School (UMMS) has ... and Drug Administration (FDA) for MBL-HCV1, a monoclonal antibody ... patients receiving a liver transplant. Complications from ... liver transplantation today. For patients with end-stage liver disease ...
... , Dec. 4, 2013 /PRNewswire-iReach/ -- The 2013 ... and figures. Worldwide markets for biometrics are poised ... electronics in their personal life, protection of individual ... protect individual information. (Photo: http://photos.prnewswire.com/prnh/20131204/MN27463 ...
Cached Biology News:University of Tennessee study finds crocodiles are cleverer than previously thought 2MassBiologics receives orphan drug status from FDA for hepatitis C treatment 2Biometrics Market Forecasts: Fingerprint Technologies, Facial and Iris Reading Algorithms Analyzed in New Research Reports 2Biometrics Market Forecasts: Fingerprint Technologies, Facial and Iris Reading Algorithms Analyzed in New Research Reports 3Biometrics Market Forecasts: Fingerprint Technologies, Facial and Iris Reading Algorithms Analyzed in New Research Reports 4Biometrics Market Forecasts: Fingerprint Technologies, Facial and Iris Reading Algorithms Analyzed in New Research Reports 5
Preadipocyte factor-1 [Pref-1, DLK-1], C-terminal...
Bag-1 (K-20)...
IC50: 35 ng/ml · Limit of detection: 8 ng/ml...
... PGE2-d4 contains 4 deuterium atoms at ... It is intended for use as an ... E2 (PGE2) by GC- or LC-mass spectrometry. ... products of arachidonic acid and one of ...
Biology Products: